Biologics for Psoriasis.
| Autor: | Wride AM; Department of Dermatology, Yale School of Medicine, Yale University, 15 York Street, New Haven, CT 06510, USA., Chen GF; Department of Dermatology, Yale School of Medicine, Yale University, 15 York Street, New Haven, CT 06510, USA., Spaulding SL; Department of Dermatology, Yale School of Medicine, Yale University, 15 York Street, New Haven, CT 06510, USA., Tkachenko E; Department of Dermatology, Yale School of Medicine, Yale University, 15 York Street, New Haven, CT 06510, USA., Cohen JM; Department of Dermatology, Yale School of Medicine, Yale University, 15 York Street, New Haven, CT 06510, USA. Electronic address: jeffrey.m.cohen@yale.edu. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Dermatologic clinics [Dermatol Clin] 2024 Jul; Vol. 42 (3), pp. 339-355. Date of Electronic Publication: 2024 Mar 13. |
| DOI: | 10.1016/j.det.2024.02.001 |
| Abstrakt: | Biologic therapies targeting tumor necrosis factor alpha (TNF-α) (infliximab, adalimumab, certolizumab, etanercept), the p40 subunit shared by IL-12 and IL-23 (ustekinumab), the p19 subunit of IL-23 (guselkumab, tildrakizumab, risankizumab), IL-17A (secukinumab, ixekizumab), IL-17-RA (brodalumab) and both IL-17A and IL-17F (bimekizumab) have revolutionized the treatment of psoriasis. In both the short and long term, risankizumab had highest Psoriasis Area and Severity Index 90 scores compared to other oral and injectable biologics. IL-23 inhibitors had lowest rates of short-term and long-term adverse events and most favorable long-term risk-benefit profile compared to IL-17, IL-12/23, and TNF-α inhibitors. Competing Interests: Disclosure J.M. Cohen serves on a data and safety monitoring board for Advarra. The remaining authors have no conflicts of interest to declare. (Copyright © 2024 Elsevier Inc. All rights reserved.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|